Investigating Chemobrain onset: A pilot study exploring the severity and onset of cognitive impairment
Review TypeAbstract Review Only: Reviewed by Event Host
Repository Posting Date2019-07-05T14:12:18Z
Author DetailsKelly Moore, BSN, RN, OCN, email: Kelly2.Moore@UTSouthwestern.edu. Ms. Moore has been a Registered Nurse since 2010. Since then she has worked with oncology patients in the capacity as a bedside nurse, infusion nurse, and as a nurse manager. She is a member of the American Nurses Association, Texas Nurses Association, and Oncology Nurses Association. She served as the Principal Investigator of The Chemobrain Study, which was a multi-center study that was funded by the J. Patrick Barnes research grant. Daiwai Olson, PhD, RN, CCRN, email: Daiwai.Olson@UTSouthwestern.edu.
Lead Author Sigma AffliationNon-member
Lead Author AffliationThe University of Texas Southwestern Medical Center
Level of EvidenceObservational
Research ApproachPilot/Exploratory Study
CINAHL HeadingsCognition--Drug Effects; Chemotherapy, Cancer--Adverse Effects; Oncologic Nursing; Cognition; Chemotherapy, Cancer
Background: Chemotherapy related changes in cognition fall into a cluster of symptoms commonly referred to as chemobrain. To date, nursing literature on the progression of chemobrain and tools used to describe this progression are scant. Objectives: The purpose of this pilot study was to explore the onset of chemobrain in persons who recently began chemotherapy and those who have been undergoing therapy for a longer period of time. Methods: This was a prospective, non-randomized, observational, pilot feasibility study of adult chemotherapy patients pilot that aimed to provide a foundation into nursing research examining cognitive changes associated with chemotherapy. Findings: Of 50 subjects enrolled 16 had lower scores at follow-up and 14 had improved scores comparing baseline and follow-up. According to the Trail Making A&B testing, 49 of 50 patients fell in the healthy range of cognitive functioning. Paired t-tests showed significant differences in baseline and 8-month Trail Making A scores (p<0.05), and comparing 4 and 8-month Trail Making B score (p<0.05). The mixed results suggest that Trail Making A & B may not be appropriate tests for chemotherapy associated cognitive decline in patients (chemobrain).
Funder(s)The DAISY Foundation
DescriptionThe research study is completed. At the time of submission to this repository, a manuscript was under review with the Clinical Journal of Oncology Nursing.
Conference NameOncology Nursing Society
Conference HostOncology Nursing Society
Conference LocationAnaheim, California, USA
Visits vs Downloads
Visitors - World Map
Top Visiting Countries
Top Visiting Cities
Visits (last 6 months)
Downloads (last 6 months)
Popular Works for Moore, Kelly by View
Popular Works for Moore, Kelly by Download
The citations below are meant to be used as guidelines. Patrons must make any necessary corrections before using. Pay special attention to personal names, capitalization, and dates. Always consult appropriate citation style resources for the exact formatting and punctuation guidelines.